MBX Biosciences, Inc. MBX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Liquidity | ||||||
| Current ratio | 30.8×+6.2× | 24.6×-8.3× | 33×+13.5× | 19.5×— | —— | |
| Quick ratio | 30.8×+6.2× | 24.6×-8.3× | 33×+13.5× | 19.5×— | —— | |
| Cash ratio | 3.1×-1.8× | 4.9×-13.6× | 18.5×+15.1× | 3.4×— | —— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | —— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | —— | |
| Per Share | ||||||
| Book value per share | $9.40-7.1% | $10.11-10.7% | $11.33+72.9% | $6.55-7.0% | $7.05-70.9% | |
| Valuation | ||||||
| Market capitalization | $1.42B+0.1% | $1.42B+81.0% | $782.52M— | —— | —— | |
| Enterprise value | $1.37B+2.4% | $1.34B+140% | $560.02M— | —— | —— | |
| Price / book | 3.2×-0.6× | 3.8×+1.8× | 2×— | —— | —— | |
| Free cash flow yield | -5.6%+0.2pp | -5.8%+4.3pp | -10.1%— | —— | —— | |
| Earnings yield | -6.1%0.0pp | -6.1%+4.1pp | -10.3%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do MBX Biosciences, Inc.'s ratios come from?
- Every ratio is computed from MBX Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.